You are here

P&T® Journal contents for December 2009


In the second of a three-part series, topics such as drug approvals and shortages, therapeutic interchanges, and pharmacoeconomic assessments are discussed.
C. Lee Ventola, MS
Research has addressed individual ADHD drugs, but few head-to-head trials have been conducted. In a meta-analysis of 32 trials, variable drug effects were noted.
Stephen V. Faraone, PhD
Valuable Insight or Government Intrusion?
Comparative effectiveness research has the potential to direct health care spending toward effective therapies and to assist P&T committees. However, some experts question its potential benefit, and others say that collecting the evidence might not be that easy.
F. Randy Vogenberg, RPh, PhD
Pay-for-Delay and Authorized Generics Back in the Spotlight
Blogs in health care and law are abuzz over a bill to restrict drug companies from “pay-for-delay” patent settlements that postpone the introduction of generics.
Miriam Reisman
Meeting Highlights
Parenteral nicardipine for hypertension, omalizumab for asthma, and acquired coagulopathy from the use of topical bovine thrombin are discussed.
Walter Alexander
Drugs discussed include ofatumumab, pazopanib, and a C1 esterase inhibitor.
Marvin M. Goldenberg, PhD, RPh, MS


David B. Nash, MD, MBA, discusses the failing grade that Consumers Union (CU), publisher of Consumer Reports, has given to our present health care system — and the CU’s recommendations for reform.
David B. Nash, MD, MBA
Medication Errors
Getting to the ‘Route’ of the Problem
Matthew Grissinger, RPh, FASCP, explains how to avoid mixups with intravenous and epidural routes of administration for potassium chloride.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses some proposed changes to Medicare’s Part D program that could make formulary design more flexible and grant more authority to P&T committees.
Stephen Barlas
From Colcrys to Voreloxin, P&T presents the latest studies and information about FDA approvals, drug indications, product recalls, and industry updates.